论文部分内容阅读
目的：观察长春瑞宾加顺铂治疗晚期非小细胞肺癌的疗效及毒性。方法：３３例晚期非小细胞肺癌病人，男性２６例，女性７例，年龄５４±ｓ４ａ。用长春瑞宾加顺铂联合治疗，３ｗｋ为一个疗程，每个病人平均治疗３．０±１．０个疗程。结果：完全缓解（ＣＲ）１例，部分缓解（ＰＲ）１６例，总有效率（ＣＲ＋ＰＲ）５２％，完全缓解率３％。全组出现血液系统毒性ＩＩＩ度５２例次，ＩＶ度１１例次；神经系统毒性Ｉ度７例次，未见ＩＩ度以上毒性；出现ＡＬＴ轻度升高者４例次，ＢＵＮ轻度升高者１例次。副作用均能耐受。结论：长春瑞宾加顺铂联合方案治疗非小细胞肺癌疗效满意。
Objective: To observe the efficacy and toxicity of vinorelbine plus cisplatin in the treatment of advanced non-small cell lung cancer. Methods: Thirty-three patients with advanced non-small-cell lung cancer included 26 males and 7 females, age 54±s4a. With the combination of vinorelbine plus cisplatin, 3wk was a course of treatment, and each patient received an average of 3.0±1.0 courses of treatment. Results: 1 case of complete remission (CR), 16 cases of partial remission (PR), total effective rate (CR+PR) of 52%, complete remission rate of 3%. There were 52 cases of grade III hemotoxin in the whole group, 11 cases of IV degree, 7 cases of degree of neurotoxicity, no grade II or more toxicity, and 4 cases of mild elevation of ALT. BUN increased slightly. 1 case times. Side effects can be tolerated. Conclusion: The combination of vinorelbine plus cisplatin in the treatment of non-small cell lung cancer is satisfactory.